Novel cyanopyridine derivatives useful in the treatment of cancer and other disorders

Abstract

This invention relates to novel diaryl ureas of Formula (I), pharmaceutical compositions containing such compounds and the use of those compounds or compositions for treating hyperproliferative and angiogenesis disorders, as a sole agent or in combination with cytotoxic therapies.

Description

[0001] related application [0002] This application claims priority to applications 60 / 450,323, filed February 28, 2003, 60 / 450,324, filed February 28, 2003, and 60 / 450,348, filed February 28, 2003. technical field [0003] The present invention relates to novel compounds, pharmaceutical compositions containing such compounds and the use of these compounds or compositions as single active agents or in combination with other active ingredients such as cytotoxic treatments for the treatment of hyperproliferative and angiogenic disorders. Background of the invention [0004] Activation of the Ras signaling pathway represents a cascade of events with profound effects on cell proliferation, differentiation and transformation. Raf kinases, as downstream effectors of Ras, are considered to be key transmitters of these signals from cell surface receptors to the nucleus (Lowy, D.R.; Willumsen, B.M. Ann. Rev. Biochem. 1993, 62, 851; Bos, J.L. Cancer Res .1989, 49, 4682). It has bee...

AI Technical Summary

Problems solved by technology

[0014] For example, under extreme hypoxia, overexpression of VEGF can cause intraocular angiogenesis, resulting in hyperproliferation of blood vessels, and eventually blindness

Images